New drug cocktail aims to shrink pancreatic tumors before surgery

NCT ID NCT07691593

Not yet recruiting Disease control Sponsor: Changhai Hospital Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the experimental drug HRS-4642 to standard chemotherapy, with or without the immunotherapy adebrelimab, can shrink pancreatic tumors before surgery. The study enrolls adults aged 18-70 with pancreatic ductal adenocarcinoma who have at least one measurable tumor. Researchers will monitor side effects and measure how many tumors respond or disappear completely after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-4642, chemotherapy (NALIRIFOX), and adebrelimab
What this could lead to: If successful, this combination could shrink pancreatic tumors before surgery, potentially improving surgical outcomes and long-term survival.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results may not apply to all patients. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.